Feasibility of a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and Labrador
Peritoneal carcinomatosis is a common presentation found in advanced-stage gastrointestinal (GI) and gynecological cancers. Combined cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with significant survival benefits for select patients. CRS/HIPEC is no...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Onco |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-7523/5/2/16 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849425182183129088 |
|---|---|
| author | Kala Hickey Stephanie Gill Zoë Breen Kaitlyn Harding Hannah Yaremko Alex Mathieson Patti Power David Pace Joannie Neveu |
| author_facet | Kala Hickey Stephanie Gill Zoë Breen Kaitlyn Harding Hannah Yaremko Alex Mathieson Patti Power David Pace Joannie Neveu |
| author_sort | Kala Hickey |
| collection | DOAJ |
| description | Peritoneal carcinomatosis is a common presentation found in advanced-stage gastrointestinal (GI) and gynecological cancers. Combined cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with significant survival benefits for select patients. CRS/HIPEC is not currently provided in Newfoundland and Labrador (NL). The Canadian HIPEC Collaborative Group recommends that centres complete a minimum of one case monthly to maintain competency and achieve good outcomes. Thus, we aimed to demonstrate that the annual patient volume in NL justifies the feasibility of implementing a combined surgical and gynecological oncology CRS/HIPEC program. Methods: A retrospective chart review of the NL Cancer Care Registry identified patients with stage IV colorectal, appendiceal, or gastric cancer and stage III to IV epithelial ovarian cancer over a 1-year period (1 January 2020–31 December 2020) to identify the number of patients meeting the criteria for CRS/HIPEC and/or those referred out of province to receive the treatment. The results are presented as proportions and percentages. Results: Thirty-one patients were eligible to receive CRS/HIPEC during the study period (11 GI, 20 gynecological). Of the GI patients, 63% were referred out of province for the procedure. Gynecological patients underwent CRS and systemic therapy +/− outpatient intraperitoneal chemotherapy in NL. Conclusions: Allowing patients to receive this standard of care treatment near home reduces financial, social, and emotional stressors. Our results confirm a sufficient patient volume to support a combined CRS/HIPEC program in NL. The implementation of this program will require multidisciplinary collaboration, specialized training, equipment, and protocol development. |
| format | Article |
| id | doaj-art-3e8ea9fa215546da9bd9ed386c2d0df4 |
| institution | Kabale University |
| issn | 2673-7523 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Onco |
| spelling | doaj-art-3e8ea9fa215546da9bd9ed386c2d0df42025-08-20T03:29:51ZengMDPI AGOnco2673-75232025-04-01521610.3390/onco5020016Feasibility of a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and LabradorKala Hickey0Stephanie Gill1Zoë Breen2Kaitlyn Harding3Hannah Yaremko4Alex Mathieson5Patti Power6David Pace7Joannie Neveu8Department of General Surgery, Faculty of Medicine, Memorial University, St. John’s, NL A1C 3V6, CanadaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Memorial University, St. John’s, NL A1C 3V6, CanadaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Memorial University, St. John’s, NL A1C 3V6, CanadaDepartment of General Surgery, Faculty of Medicine, Memorial University, St. John’s, NL A1C 3V6, CanadaDepartment of General Surgery, Faculty of Medicine, Memorial University, St. John’s, NL A1C 3V6, CanadaDepartment of General Surgery, Faculty of Medicine, Memorial University, St. John’s, NL A1C 3V6, CanadaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Memorial University, St. John’s, NL A1C 3V6, CanadaDepartment of General Surgery, Faculty of Medicine, Memorial University, St. John’s, NL A1C 3V6, CanadaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Memorial University, St. John’s, NL A1C 3V6, CanadaPeritoneal carcinomatosis is a common presentation found in advanced-stage gastrointestinal (GI) and gynecological cancers. Combined cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with significant survival benefits for select patients. CRS/HIPEC is not currently provided in Newfoundland and Labrador (NL). The Canadian HIPEC Collaborative Group recommends that centres complete a minimum of one case monthly to maintain competency and achieve good outcomes. Thus, we aimed to demonstrate that the annual patient volume in NL justifies the feasibility of implementing a combined surgical and gynecological oncology CRS/HIPEC program. Methods: A retrospective chart review of the NL Cancer Care Registry identified patients with stage IV colorectal, appendiceal, or gastric cancer and stage III to IV epithelial ovarian cancer over a 1-year period (1 January 2020–31 December 2020) to identify the number of patients meeting the criteria for CRS/HIPEC and/or those referred out of province to receive the treatment. The results are presented as proportions and percentages. Results: Thirty-one patients were eligible to receive CRS/HIPEC during the study period (11 GI, 20 gynecological). Of the GI patients, 63% were referred out of province for the procedure. Gynecological patients underwent CRS and systemic therapy +/− outpatient intraperitoneal chemotherapy in NL. Conclusions: Allowing patients to receive this standard of care treatment near home reduces financial, social, and emotional stressors. Our results confirm a sufficient patient volume to support a combined CRS/HIPEC program in NL. The implementation of this program will require multidisciplinary collaboration, specialized training, equipment, and protocol development.https://www.mdpi.com/2673-7523/5/2/16HIPECperitoneal surface malignancycarcinomatosiscytoreductionfeasibility |
| spellingShingle | Kala Hickey Stephanie Gill Zoë Breen Kaitlyn Harding Hannah Yaremko Alex Mathieson Patti Power David Pace Joannie Neveu Feasibility of a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and Labrador Onco HIPEC peritoneal surface malignancy carcinomatosis cytoreduction feasibility |
| title | Feasibility of a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and Labrador |
| title_full | Feasibility of a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and Labrador |
| title_fullStr | Feasibility of a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and Labrador |
| title_full_unstemmed | Feasibility of a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and Labrador |
| title_short | Feasibility of a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and Labrador |
| title_sort | feasibility of a hyperthermic intraperitoneal chemotherapy hipec program for gastrointestinal and gynecological cancer care in newfoundland and labrador |
| topic | HIPEC peritoneal surface malignancy carcinomatosis cytoreduction feasibility |
| url | https://www.mdpi.com/2673-7523/5/2/16 |
| work_keys_str_mv | AT kalahickey feasibilityofahyperthermicintraperitonealchemotherapyhipecprogramforgastrointestinalandgynecologicalcancercareinnewfoundlandandlabrador AT stephaniegill feasibilityofahyperthermicintraperitonealchemotherapyhipecprogramforgastrointestinalandgynecologicalcancercareinnewfoundlandandlabrador AT zoebreen feasibilityofahyperthermicintraperitonealchemotherapyhipecprogramforgastrointestinalandgynecologicalcancercareinnewfoundlandandlabrador AT kaitlynharding feasibilityofahyperthermicintraperitonealchemotherapyhipecprogramforgastrointestinalandgynecologicalcancercareinnewfoundlandandlabrador AT hannahyaremko feasibilityofahyperthermicintraperitonealchemotherapyhipecprogramforgastrointestinalandgynecologicalcancercareinnewfoundlandandlabrador AT alexmathieson feasibilityofahyperthermicintraperitonealchemotherapyhipecprogramforgastrointestinalandgynecologicalcancercareinnewfoundlandandlabrador AT pattipower feasibilityofahyperthermicintraperitonealchemotherapyhipecprogramforgastrointestinalandgynecologicalcancercareinnewfoundlandandlabrador AT davidpace feasibilityofahyperthermicintraperitonealchemotherapyhipecprogramforgastrointestinalandgynecologicalcancercareinnewfoundlandandlabrador AT joannieneveu feasibilityofahyperthermicintraperitonealchemotherapyhipecprogramforgastrointestinalandgynecologicalcancercareinnewfoundlandandlabrador |